UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 22, 2011
MEDCATH CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 000-33009 | 56-2248952 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 10720 Sikes
Place Charlotte, North Carolina |
28277 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (704) 708-6600
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
MedCath Corporation (the “Company”) announced today that the Company’s Board of Directors declared a liquidating distribution of $6.85 per share of common stock outstanding, which will be paid October 13, 2011 to stockholders of record on October 6, 2011. The amount of the liquidating distribution is consistent with the amount of the anticipated initial liquidating distribution described in the proxy statement filed with the Securities and Exchange Commission on August 17, 2011.
The distribution is expected to be treated as a return of capital for tax reporting purposes, but stockholders will receive further information on Form 1099 and are encouraged to consult with their own tax advisors regarding the tax treatment of the distribution.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
MEDCATH CORPORATION
Date: September 22, 2011
By: /s/ James A. Parker
James A. Parker
Executive Vice President and
Chief Financial
Officer